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Abstract 
Aims: Curcumin is a lead compound of the rhizomes of Curcuma longa and possess a broad range of pharmaco‑
logical activities. Chemically, curcumin is 1,3‑dicarbonyl class of compound, which exhibits keto‑enol tautomerism. 
Despite of its strong biological properties, curcumin has yet been recommended as a therapeutic agent because of its 
poor bioavailability.
Main methods: A curcumin derivative (Z)‑3‑hydroxy‑1‑(2‑hydroxyphenyl)‑3‑phenylprop‑2‑en‑1‑one (DK1) was 
synthesized and its cytotoxicity was tested on breast cancer cell MCF‑7 and normal cell MCF‑10A using MTT assay. 
Meanwhile, cell cycle regulation and apoptosis on MCF‑7 cell were evaluated using flow cytometry. Regulation of cell 
cycle and apoptosis related genes expression was investigated by quantitative real time polymerase chain reaction 
(qRT‑PCR), western blot and caspases activity analyses. Activation of oxidative stress on MCF‑7 were evaluated by 
measuring ROS and GSH levels.
Key findings: DK1 was found to possess selective cytotoxicity on breast cancer MCF‑7 cell than normal MCF‑10A 
cell. Flow cytometry cell cycle and AnnexinV/PI analyses reported that DK1 effectively arrested MCF‑7 at G2/M phase 
and induced apoptosis after 72 h of incubation than curcumin. Upregulation of p53, p21 and downregulation of 
PLK‑1 subsequently promote phosphorylation of CDC2 which were found contributed to the arrest of G2/M phase. 
Moreover, increased of reactive oxygen species and reduced of antioxidant glutathione level correlate with apoptosis 
observed with raised of cytochrome c and active caspase 9.
Significance: DK1 was found to be more effective in inducing cell cycle arrest and apoptosis against MCF‑7 cell with 
much higher selectivity index of MCF‑10A/MCF‑7 than curcumin, which might be contributed by the overexpression 
of p53 protein.
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Background
Breast cancer contributes the highest to the total popu-
lation of cancer cases and cancer-related mortality in 
women [1]. With the passage of time, it becomes highly 
aggressive disease and common cause of cancer death in 
women. The potential cause of breast cancer is believed 
due to the presence of estrogen receptor beta (ERb). Tri-
ple-negative breast cancer (TNBC) is a subtype of breast 
cancer defined by lack of expression of estrogen receptor 
alpha progesterone receptor and considered as the worst 
among all types of breast cancer [2–4]. Abnormal regu-
lation of cell cycle and inhibition of apoptosis signaling 
pathways were commonly found in cancer cells. Chem-
otherapy targeting cancer cell with abnormal cell cycle 
profile or by inducing apoptosis have been widely used in 
cancer treatment [5]. However, the conventional chemo 
and hormone therapeutic agents have been reported 
associated with side effects, which were contributed by 
their cytotoxicity [6, 7]. Thus, effort to search for the 
alternative cytotoxic agents that target on the cell cycle 
progression and induce apoptosis specifically on cancer 
without harming normal cells is on-going [8].
Curcumin (diferuloylmethane), a member of the cur-
cuminoid family, is the major active component of tur-
meric powder extracted from the rhizomes of Curcuma 
longa. It has been widely used as food additive and cos-
metic ingredient. Over the past few decades, curcumin 
has been proven to be a remarkable drug for vast number 
of biological activities such as anti-carcinogenic [9–13], 
anti-malarial [14], antioxidant, anti-mutagenic, antibac-
terial [15, 16], anti-angiogenic [13], immunomodulatory 
[17] chemo-preventive [1, 12], anti- leishmaniasis [18] 
and anti-inflammatory effects [19].
Nevertheless, due to its partial solubility in water, cur-
cumin has poor bioavailability and its clinical efficacy is 
rather limited [20]. Over the past few years, bioavailability 
issues related with poor absorption, distribution, metabo-
lism and excretion of curcumin in serum levels and have 
limited its usage [21]. Although plants based natural com-
pounds have been identified as potential source of anti-
cancer agents due to its chemical diversity [22], chemically 
synthesized compounds have offered great potential to 
modify the natural compound structure to achieve better 
selectivity against cancer cell line [8]. Several curcumin 
derivatives were found to be more effective as anti-inflam-
matory agents than curcumin itself [19, 23]. Previously, 
we have reported the antihyperalgesic and antinociceptive 
activities of synthetic curcuminoid derivative, 2,6-bis-4-
(hydroxy-3-methoxybenzilidine)-cyclohexanone in ani-
mal models [24, 25].
A simple curcuminoid, namely (Z)-3-hydroxy-1-(2-
hydroxyphenyl)-3-phenylprop-2-en-1-one (DK1) was 
synthesized (Fig.  1). The compound DK1 was obtained 
as 100% pure crystals form and the structure was con-
firmed by single X-ray analysis [26]. Furthermore, the 
cytotoxicity and selectivity of DK1 on breast cancer and 
normal cell lines were also evaluated. Subsequently, the 
mechanism that alters cell cycle progression and apop-
tosis of DK1 treated MCF-7 breast cancer cell line was 
also determined. Our results provide the evidence that 
DK1 treatment induced p21 regulated G2/M phase 
arrest while promoted generation of reactive oxygen spe-
cies (ROS) causing activation of DNA damage via p53 
dependent apoptosis on MCF-7 breast cancer cell.
Methods
Synthesis and characterization of DK1
Compound DK1 was synthesized by Baker-Venkatara-
man rearrangement. A mixture of 2-hydroxyacetophe-
none 25.0  mol (3.5  g) and 21  mol (3.5  mL) of benzoyl 
chloride were added in a round bottle flask and stirred at 
30  °C. About 30 mL pyridine anhydrous was added in a 
warm solution of above mixture and stirred for 1 h. After 
reaction completion, the product was neutralize with 
5% HCl in 95  mL ice water and white crystalline com-
pound was floating on the surface of water. The prod-
ucts 2-acetylphenyl benzoate was filter and washed with 
methanol and dried over sodium sulphate anhydrous. In 
the second step, the 2-acetylphenyl benzoate 12.5  mol 
(3.0  g) was dissolved in 15  mL pyridine anhydrous and 
stirred in a 100 mL beaker. About 0.5 g KOH was added 
in beaker during stirring condition and mixture were 
heated at 20 °C for 30 min. The products was neutralize 
with 15  mL acetic acid in ice water. The final the prod-
uct was extracted with ethyl acetate and crystallized 
using methanol. The product was obtained as light yel-
low prism crystals and structure was confirmed by single 
X-ray and 1H-NMR data [26].
Fig. 1 Synthesis of (Z)‑3‑hydroxy‑1‑(2‑hydroxyphenyl)‑3‑phenylprop‑2‑en‑1‑one (DK1)
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Synthesis of (Z)‑3‑hydroxy‑1‑(2‑hydroxyphenyl)‑ 
3‑phenylprop‑2‑en‑1‑one (DK1)
Synthesized DK1 (Fig.  1) was the light yellow crystals 
with 96% yield and melting point ranging between 132 
and 134  °C. IR (CHCl3)/cm: 36,500 (broad OH), 2955 
(C–H stretch), 1658 (C=O), 1610 (C=C), 1516 (C=C), 
1269 (C–O aromatic), 1074, 1001, 1H NMR (500  MHz, 
CDCl3): δ 15.50 (enol OH, C-3), 12.07 (OH, C-2″), 7.90 
(s, 1H, C-2), 7.89 (d, 2H, J = 1.5 Hz, C-2′ & C-6′), 7.67 (m, 
3H, C-3′, 4′, & C-5′), 7.77 (s, 1H, C-6″) J = 3.0 Hz, 1H, 
H-4), 6.98 (m, 3H C-3″, 4″, & C-5″). EIMS m/z (rel. int.) 
calcd for C15H12O3 [M+]: m/z = 240.2.
Cell lines
Promyelocytic leukemia HL60, hepatoblastoma HepG2, 
breast cancer MCF-7 and MDA-MB-231 cells were pur-
chased from ATCC (USA) and cultured in RPMI-1640 
media (Sigma, USA), supplemented with 10% fetal bovine 
serum (FBS) (PAA, USA). Normal epithelial MCF-10A cells 
(ATCC, USA) was maintain in DMEM-F12 (Sigma, USA) 
supplemented with hydrocortisone (0.5  μg/mL), insu-
lin (10  μg/mL), human epidermal growth factor (hEGF) 
(20 ng/mL) (Sigma, USA) and 10% FBS (PAA, USA).
MTT cell viability assay and DK1 selective index
MTT cell viability assay [27] was used to evaluate the 
effect of DK1 on viability of HL-60, HepG2, MCF-7, 
MDA-MB-231 and MCF-10A cells. Briefly, each type of 
cells (8  ×  104cells/well) was seeded in 96-well plate in 
37  °C CO2 incubator overnight. Then, DK1 was added 
at concentration ranging between 200 and 3.125 µM by 
twofold serial dilution. Untreated control was prepared 
simultaneously. After that, the cells were incubated for 
24, 48 and 72 h at 37 °C in 5% CO2 incubator. After the 
incubation period, all well was added with 20 μL of MTT 
solution (5 mg/mL) and further incubated for 3 h. Sub-
sequently, 170  μL of supernatant from each well was 
discarded, 100  μL of dimethyl sulfoxide (DMSO) was 
added to solubilize the purple formazan crystal and the 
absorbance was measured at a wavelength of 570  nm 
by Enzyme-linked immunosorbent assay (ELISA) plate 
reader (Bio-tek instruments, USA). All cell lines were 
assayed for three biological replicates each with tripli-
cates. Percentage of cell viability was calculated using the 
following formula:
IC50 value (concentration of DK1 that reduce 50% of 
cell viability compared to control cell) was determined 
from the graph of cell viability (%) vs DK1 concentration. 
Subsequently, selective index, which indicating selectiv-
ity of DK1 against cancerous and normal breast cell lines, 
was calculated by:
Cell viability (%) = (OD sample/OD control)× 100%
MCF‑7 cell treatment
MCF-7 cell, which was the most sensitive cell line to 
DK1, were seeded overnight in six well plate at 8 × 104 
cells/mL. After that, 25  µM of DK1 was added to the 
MCF-7. Untreated control and curcumin at 30 µM treat-
ment were prepared simultaneously. After 24, 48 or 72 h 
of incubation control and treated MCF-7 cells were 
detached using TrypLE (Invitrogen, USA), washed with 
PBS (Sigma, USA) and subjected to the following assays. 
Curcumin treated cells were harvested at 72 h.
Light and fluorescent microscopic observation
Prior to harvest the cell, morphology of control and DK1 
treated MCF-7 was observed using light microscope. In 
addition, harvested control and treated MCF-7 cells were 
resuspended in 100 μL of Phosphate buffer saline (PBS), 
stained with 10 μg/mL of Acridine orange (AO) and pro-
pidium iodide (PI) and viewed under fluorescent micro-
scope (Nikon, Japan).
Flow cytometry AnnexinV‑FITC/PI apoptosis analysis
Apoptosis of DK1 treated MCF-7 was compared with the 
control cell by Flow cytometry AnnexinV-FITC/PI apop-
tosis assay. Briefly, harvested cells were resuspended in 
100 μL of 1× binding buffer and stained with 5 μL each 
of AnnexinV-FITC and propidiumiodide. After 15  min 
of incubation, the cells were added with 400  μL of 1× 
binding buffer and subjected to BD FACS Calibur flow 
cytometer analysis using BD Cell Quest Pro software 
(Becton–Dickinson, USA).
Intracellular glutathione (GSH) and reactive oxygen species 
(ROS) detection
Harvested cell was subjected to two times of freeze and 
thaw in 100 μL of PBS. The lysed cell was then pelleted 
and the supernatant was subjected to GSH and ROS 
quantification using Glutathione assay kit (Sigma, USA) 
and OxiSelect ROS assay kit (Cell Biolabs, USA) accord-
ing to manufacturers’ protocol.
For GSH quantification, 10 μL of cell lysate supernatant 
was added with 150 μL of working solution (1.5 mg/mL 
DTNB solution, 6  units/mL glutathione reductase and 
1× assay buffer), incubated for 5  min and added with 
50 μL of NADPH solution (0.16 mg/mL). The absorbance 
was read at a wavelength of 412 nm by ELISA plate reader 
(Bio-Tek instrument, USA) for every minute in duration 
of 5  min. For intracellular ROS quantification, super-
natant was added with 10 μM DCFH-DA for 30 min at 
37 °C. Then, the fluorescence intensity of DCFH-DA was 
Selective index (SI)
=
(IC50 of DK1 on normal MCF-10A cell line)
IC50 on breast cancerous cell line (HL60/HepG2/MCF-7/MDA-MB-231)
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measured using microplate fluorometer (Thermo Scien-
tific, USA) with a 485/538 nm filter. Fold change of GSH 
and ROS was calculated by dividing absorbance or fluo-
rescence intensity of DK1 treated MCF-7 with untreated 
control MCF-7.
Active caspase 9, cytochrome c
The level of active caspase 9 and cytochrome c of the 
control and DK1 treated MCF-7 were quantified using 
CaspGLOW Red Active Caspase-9 staining kit (BioVi-
sion, USA) and human cytochrome c platinum ELISA 
(eBioscience Affymetrix, USA), respectively according 
to manufacturers’ protocol. Fold change of caspase 9 and 
cytochrome c was calculated by dividing fluorescence 
intensity or absorbance of DK1 treated MCF-7 with 
untreated control MCF-7.
Western blot analysis
Total protein was extracted from harvested cell with 
Radioimmunoprecipitation assay (RIPA) buffer sup-
plemented with phosphatase inhibitor cocktail (Roche, 
Canada) and the concentration was quantified by Brad-
ford assay (Sigma, USA). Then, 100  μg of extracted 
protein was subjected to sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) (Bio-Rad, 
USA), transferred to nitrocellulose membrane, block 
with 0.5% skimmed milk overnight, washed with Tris-
buffered saline tween (TBST) buffer and incubated with 
primary antibodies (anti-CDC2, anti-pCDC2 (Tyr15), 
anti-p53, and anti-β-actin at a dilution of 1:1000 
(Abcam, USA) for 1  h. After that, membranes were 
washed, incubated with 1:5000 diluted goat anti-rabbit 
IgG H&L conjugated to Alkaline Phosphatase (Abcam, 
USA) and developed under chemiluminescence condi-
tion (Super Signal West Pico, Pierce, USA) using the 
ChemiDoc XRS (Bio-Rad, USA). Differential level of 
evaluated protein in control and DK1 treated MCF-7 
was calculated based on the bands intensity analyzed 
using the Quantity One 1D Analysis software (Bio-rad, 
USA).
Flow cytometry cell cycle analysis
Cell cycle progression of control and DK1 treated 
MCF-7 was analysed using BD FACS Calibur flow 
cytometer (Becton–Dickinson, USA). Briefly, har-
vested cells were added with 250  μL of trypsin buffer 
with 10  min incubation, followed by 200  μL of trypsin 
inhibitor with RNase buffer with 10  min incubation, 
and finally stained with 200 μL of propidium iodide (PI) 
from BD Cycletest Plus kit (Becton–Dickinson, USA). 
All stained cells were subjected to BD FACS Calibur 
flow cytometer analysis using BD Cell Quest Pro soft-
ware (Becton–Dickinson, USA).
Quantitative reverse transcription real time PCR assay
RNeasy mini plus kit (Qiagen, USA) was used to extract 
total RNAs from control and DK1 treated MCF-7 cells. 
The extracted RNAs were subjected to nano-drop spec-
trophotometer (Eppendorf, Germany) for purity and con-
centration evaluation and were converted to cDNA using 
iScriptcDNA synthesis kit (Bio-Rad, USA). Reverse and 
forward primers for target genes (p21, PLK-1, WEE-1) 
and housekeeping genes (β-actin, 18srRNA and GAPDH) 
were listed in Table  1. The expression level of target 
genes was quantified by quantitative real time polymer-
ase chain reaction (qRT-PCR) using SYBR select master 
mix (Life Technologies, USA) on iQ-5 Real Time PCR 
machine (Bio-Rad, USA). Differential expression of target 
genes were normalized against three housekeeping genes 
between control and DK1 treated MCF-7 cell using iQ5 
optical system software (Bio-Rad, USA) [28].
Statistical analysis
All assays were carried out in three biological replicates 
and statistical significant among different time point of 
DK1 treatment to control cell were analyzed using one-
way analysis of variance (ANOVA) by SPSS 15 software. 
Duncan’s multiple range tests was used for post hoc anal-
ysis and p value <0.05 compared to untreated control was 
regarded as significant.
Results
DK1 selectively induced cytotoxicity against MCF‑7 breast 
cancer cells
MTT assay was used to evaluate the cytotoxicity of 
DK1 on promyelocytic leukemia HL60, hepatoblastoma 
HepG2, breast cancer MCF-7 and MDA-MB-231 cell 
lines. Normal breast epithelial MCF-10A cell line was 
used as normal control for calculation of selectivity index 
(SI) of DK1 on normal cell comparing to cancerous cell 
lines. Table  2 summarized the IC50 value and selective 
Table 1 The accession number and  sequence of  the prim-
ers used in the quantitative real-time PCR assay
Accession number Gene Sequence
NM_001101.3 ACTB F: 5′‑AGAGCTACGAGCTGCCTGAC‑3′
R: 5′‑AGCACTGTGTTGGCGTACAG‑3′
NM_002046.4 GAPDH F: 5‑GGATTTGGTCGTATTGGGC‑3
R: 5‑TGGAAGATGGTGATGGGATT‑3
HQ387008.1 18S rRNA F: 5‑GTAACCCGTTGAACCCCATT‑3
R: 5‑CCATCCAATCGGTAGTAGCG ‑3
NM_005030.3 PLK1 F: 5‑CCTGCACCGAAACCGAGTTAT‑3
R: 5‑CCGTCATATTCGACTTTGGTTGC‑3
NM_001143976.1 WEE‑1 F: 5‑GGGAATTTGATGTGCGACAG‑3
R: 5‑CTTCAAGCTCATAATCACTGGCT‑3
NM_001220778.1 p21 F: 5‑TGTCCGTCAGAACCCATGC‑3
R: 5‑AAAGTCGAAGTTCCATCGCTC‑3
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index of DK1 and curcumin on all the tested cell lines at 
24, 48 and 72  h. DK1 has shown time dependent cyto-
toxicity against all the tested cell lines with the best cyto-
toxic effect on breast cancer cells particularly on MCF-7 
at 72  h (25  μM) while lowest sensitivity against normal 
MCF-10A cell at 24 h where no IC50 value was recorded 
up to 208 μM. In terms of selectivity, DK1 showed bet-
ter cytotoxicity on both cancerous cells than normal cell 
with the highest selective index of 4.17 in MCF-7/MCF-
10A at 72 h. On the other hand, curcumin was recorded 
with greater cytotoxic effect on all the tested cancer cell 
lines except MCF-7 cells compared to DK1. DK1, which 
was more effective in MCF-7 cells, possessed much 
higher selectivity index of MCF-10A/MCF-7 compared 
to curcumin. Since DK1 possessed the highest efficacy 
and selectivity against MCF-7 cell better than curcumin, 
details of cell cycle regulation and cell death induction of 
DK1 on MCF-7 were further evaluated at IC50 value of 
25 µM at 24, 48 and 72 h.
DK1 induced p53 mediated apoptosis through induction 
of ROS and inhibition of GSH
Light microscope observation presented a distinct differ-
ent between morphology of control and 72 h-DK1 treated 
MCF-7 where control cell was confluent with well spread, 
adhered and extended morphology (Fig. 2a). In contrast, 
DK1 reduced the cell number and induced cell shrinkage 
on MCF-7 after 72 h of incubation (Fig. 2b). Fluorescence 
microscopic analysis using acridine orange and propid-
ium iodide (PI) staining was used to evaluate the mode of 
cell death on MCF-7 induced by DK1. Acridine orange is 
a membrane permeable DNA dye that stained the viable 
cell as green. On the other hand, propidium iodide is a 
membrane impermeable DNA dye. It enters and binds 
with DNA to show red–orange colour when the cell loss 
the membrane and become permeable during apoptosis 
or necrosis [29]. Figure 2c shows that control MCF-7 cell 
was stained as green intact cell while DK1 treatment has 
induced apoptotic related morphological changes such 
as membrane blebbing, chromatin condensation and cell 
shrinkage (Fig.  2d). Random scoring based on 200 cells 
has recorded ~12.5 and ~31% of the cells were undergone 
apoptosis or late apoptosis/necrosis (Fig. 2e). This result 
was further supported by the flow cytometry AnnexinV/
PI apoptosis assay through evaluation on the externaliza-
tion of phosphatidylserine and loss of membrane integ-
rity. Early apoptosis is indicated by binding of AnnexinV 
to externalise phosphatidylserine while late apoptosis or 
necrosis is shown by both binding of AnnexinV to phos-
phatidylserine and staining of propidium iodide to the 
DNA via loss of membrane integrity. Significant increase 
(p < 0.05) of early (~14%) and late apoptosis (~39%) was 
only observed after 72 h of DK1 treatment (Fig. 3). This 
result was similar to the percentage of apoptotic and late 
apoptotic cell as detected in fluorescent microscopic 
observation (Fig.  2e). Comparatively, 72  h of curcumin 
treatment only induced 15% of MCF-7 cells to late apop-
tosis, which was 2.6-folds lower than DK1 treatment at 
72 h (Fig. 3).
To determine the contribution of oxidative stress in the 
induction of apoptosis by DK1, level of ROS and anti-
oxidant peptide GSH were determined. DK1 was able 
to significantly reduce the level of antioxidant peptide 
GSH (48 h: ~2.2-fold; 72 h: ~3.3-fold) and promote gen-
eration of ROS (48  h: ~1.9-fold; 72  h: ~2.6-fold) in the 
MCF-7 cell compared to control (Fig. 4). This effect was 
associated with promotion of p53 (48 h: ~1.6-fold; 72 h: 
~2.0-fold) (Fig.  5), cytochrome c (48  h: ~2.1-fold; 72  h: 
~2.8-fold) and active caspase 9 (48  h: ~1.9-fold; 72  h: 
~2.4-fold) (Fig. 4) as observed in western blot, ELISA and 
fluorometry analyses, respectively. On the other hand, 
curcumin treatment induced a lower degree of deregula-
tion of apoptosis related genes or proteins, particularly 
on the p53 protein compared to DK1 (Figs. 4, 5).
DK1 induced G2/M cell cycle arrest through upregulation 
of p21 and downregulation of serine/threonine‑protein 
kinase 1 (PLK1)
Figure  6 depicts representative cell cycle histograms of 
control and 25  µM DK1 treated MCF-7 cells following 
Table 2 The values of IC50 of DK1 in MCF-7, MDA-MB231 and MCF-10A
Cell lines 24 h 48 h 72 h
DK1 (µM) Curcumin (µM) DK1 (µM) Curcumin (µM) DK1 (µM) Curcumin (µM)
HL‑60 137.61 ± 2.16 57.01 ± 3.75 123.85 ± 3.27 29.86 ± 3.11 73.39 ± 2.65 21.72 ± 1.76
HepG2 >150 ± 5.85 67.86 ± 2.88 137.61 ± 4.13 40.72 ± 2.76 64.22 ± 3.12 24.43 ± 2.25
MCF‑7 96.83 ± 4.87 40.72 ± 3.24 33.33 ± 3.50 36.58 ± 2.31 25.00 ± 3.71 30.15 ± 2.36
MDA‑MB‑231 104.17 ± 5.23 35.29 ± 4.16 45.83 ± 4.66 21.72 ± 1.87 37.50 ± 4.82 21.72 ± 3.18
MCF‑10A >208 190.02 ± 3.67 125.83 ± 3.67 114.01 ± 3.57 104.17 ± 5.21 100.44 ± 3.17
Selective index of MCF‑10A/MCF‑7 >2.17 4.67 3.75 3.50 4.17 3.33
Selective index of MCF‑10A/MDA >2.00 5.38 2.72 5.25 2.77 4.63
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24, 48 and 72 h incubation. DK1 treatment has recorded 
an increased in percentage of cell populations in G2/M 
phase (24 h: ~25%; 48 h: ~26%; 72 h: ~31%) accompanied 
by a reduction in G0/G1 phase compared to control cell 
(G2/M phase: ~18%). 72 h of curcumin treatment induced 
similar level of cell cycle arrest as DK1 treatment.
The cell cycle analysis indicates the inhibitory effect 
of DK1 on proliferation of MCF-7 cells correlated with 
G2/M arrest. Thus, qRT-PCR and Western blot analysis 
were carried out to evaluate the role of cell cycle regu-
lators associated with the DK1 induced G2/M arrest on 
MCF-7. qRT-PCR analysis shows that DK1 downregu-
lated expression of PLK1 while enhanced the expres-
sion of p21 and WEE-1 significantly (p < 0.05) compared 
to control (Fig.  7). Furthermore, western blot analysis 
showed inhibition of CDC2 due to the phosphoryla-
tion on Tyr15 indicated by the reduction of CDC2 and 
the accumulation of phospho-CDC2 (Tyr15) after treat-
ing with DK1 for 48 and 72 h (Fig. 5). On the other hand, 
curcumin treatment induced a lower degree of deregu-
lation of cell cycle regulation related genes compared to 
DK1 (Figs. 4, 7).
Fig. 2 a, b Light and c, d fluorescent microscopic analysis of control and DK1 treated MCF‑7 cell after 72 h of incubation. Cells in c, d were stained 
with acridine orange and propidium iodide. e Bar chart analysis of the percentage of viable, apoptotic and late apoptotic/necrotic of control 
and DK1 treated MCF‑7 cells via fluorescent microscopic count of 200 cells. The experiment was done in triplicate and the data are expressed as 
mean ± SE with (*p < 0.05)
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Fig. 3 Flow cytometry Annexin V apoptosis of control and DK1 (25 µM) treated MCF‑7. The experiment was done in triplicate and the data are 
expressed as mean ± SE with (*p < 0.05)
Fig. 4 Detection of the activation of caspase 9, cytochrome c, GSH and ROS levels in the control and DK1 (25 μM) treated MCF‑7 cells. The experi‑
ment was done in triplicate and the data are expressed as mean ± SE with (*p < 0.05)
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Discussion
DK1, an analogue of curcumin with lower molecular 
weight was synthesized in this study andwas found most 
sensitive to MCF-7 cell comparing to MDA-MB-231 cell 
and normal MCF-10A cell. SI based on the IC50 value of 
the compound in normal and cancerous cell line dem-
onstrates different efficacy of an evaluated compound 
in different type of cells. The higher SI value indicates 
better selectivity while low SI (generally <2) indicates 
the possibility of the compound to cause a toxicity side 
effect [8] and thus hold the value for further evaluation 
including preclinical studies using animal models. Even 
antiestrogen drug like 4-hydroxy tamoxifen has been 
reported with SI <2 [8] and this might be the reason that 
contributes to the side effect of this drug as recorded in 
clinical [6]. Thus, evaluating the SI value of a novel com-
pound shall provide a good indication to further evalu-
ate its antitumor effect both in vitro and in vivo. In this 
study, DK1 was recorded with SI values higher than 2 in 
both MCF-7 and MDA-MB-231 cell lines. Highest value 
of 4.17 SI was recorded in MCF-7 after 72 h of DK1 treat-
ment. The SI value of DK1 on MCF-7 is higher than the 
other class of compound such as anthraquinone BHAQ 
(SI: 2.31) [30] and flavokawain A (SI: 3.78) [31]. Compar-
ing to curcumin, DK1 showed better cytotoxicity as well 
as selectivity on MCF-7 cells. Previous study by Jia et al. 
[32] has reported that MCF-7 was resistant to curcumin, 
which is similar with our results. This result suggests that 
Fig. 5 Differential protein expression of. a Western blot analysis of CDC2, p‑CDC2 and p53 in MCF‑7 treated with DK1 (25 μM) for 24, 48 and 72 h. b 
Differential protein level of control and DK1 (25 μM) treated MCF‑7 cells normalised to β‑actin. The experiment was done in triplicate and the data 
are expressed as mean ± SE with *p < 0.05
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Fig. 6 Flow cytometry cycle progression analyses of control and DK1 (25 µM) treated MCF‑7. The experiment was done in triplicate and the data 
are expressed as mean ± SE with (*p < 0.05)
Fig. 7 qPCR analysis of cell cycle related genes; PLK1, p21 and WEE‑1 in MCF‑7 treated with DK1 (25 μM) for 24, 48, and 72 h. The experiment was 
done in triplicate and the data are expressed as mean ± SE with (*p < 0.05)
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DK1 was a potential specific cytotoxic agent to MCF-7 
cell line compared to curcumin. Thus, further studies to 
evaluate the details mode of cell death and mechanism 
involves were carried out.
Irregular cell cycle profile and development of anti-
apoptosis have been commonly observed in cancer cell. 
Thus, capability to induce cell cycle arrest and promote 
apoptosis is the common criteria of potential chemo-
therapeutic agents [33]. Therefore, this study was focused 
to evaluate the regulation of cell cycle profile and induc-
tion of apoptosis by DK1 on MCF-7 cell. Microscopic 
and flow cytometry analyses have shown that 25  µM of 
DK1 induced cell death through apoptosis especially after 
72  h of incubation. Accumulation of ROS and deple-
tion of antioxidant peptide (Fig. 7) was observed in DK1 
treated MCF-7 cell. A previous study has shown that 
excessive ROS induced by exogenous agents is the criti-
cal upstream event that leads to DNA damage and apop-
tosis of cancer cells through multiple signaling pathways 
[33].Tumor suppressor protein p53 has been identified 
as one of the downstream signaling protein activated by 
ROS accumulation on prostate cancer cell induced by a 
plant flavone, apigenin. This effect has given an idea that 
p53 is the predominant transcriptional regulator, which 
response to ROS-induced DNA damage [34]. Subse-
quently, p53 induces apoptosis by caspase 9 activation 
through the release of mitochondrial cytochrome c. Acti-
vation of caspase 9 in turn, leads to activation of caspase 
3, degradation of many intracellular proteins, resulting 
in the morphological and biochemical changes of apop-
tosis [35]. This mechanism was observed in DK1 treated 
MCF-7 where significant (p  <  0.05) increase of p53, 
cytochrome c, active caspase 9 were observed after 48 
and 72  h of incubation. Subsequently, apoptosis related 
characteristics such as membrane blebbing, chroma-
tin condensation, cell shrinkage and phosphatidylserine 
externalization were observed in MCF-7 after 72  h of 
DK1 treatment.
Other than apoptosis induction, DK1 was also found 
to arrest the cell cycle of MCF-7 at G2/M phase. DNA 
damage activates the G2 checkpoint mechanism to pre-
vent cell cycle progression via p53 dependent mecha-
nisms [36]. Cyclin kinase inhibitor, p21 is one of the 
downstream targets of tumor suppressor p53. Bind-
ing of CDC2 to cyclin B1 is the key checkpoint regulat-
ing progression from G2 to M transition while CDC-2 
Tyr-15 phosphorylation leads to a G2 arrest [37]. Over-
expression of p21 gene promote CDC2 (Tyr15) phospho-
rylation and thus activated G2/M cell cycle arrest [38]. 
Polo-like kinase 1 (PLK1) is a Ser/Thr kinase that plays 
pivotal roles in the activation of cyclinB1/CDC2 complex 
for transition of G2 to mitosis in cell cycle progression 
[39]. Overexpression of PLK1 has been reported in vari-
ous types of cancers and thus it has been proposed as the 
potential target for cancer therapy. In addition, WEE-1 
kinase also inactivates CDC2 activity to promote G2 
arrest [37]. Taken together, the data from this study sug-
gest that activation of p53 subsequently prevented cell 
cycle progression of MCF-7 at G2/M phase with the 
involvement of upregulation of p21 and WEE-1 gene 
together with inhibition of mitotic PLK1 followed by 
Tyr15 phosphorylation in CDC2.
Interestingly, previous study by Jia et  al. [32] has 
reported that p21 and p27 induced PI3k/Akt signaling 
pathway play the important role in regulating cell cycle 
arrest and apoptosis induction in breast cancer cells. The 
expression level of p21 and other markers under PI3k/
Akt signaling pathway were found lower in curcumin 
treated MCF-7 cells compared to curcumin treated 
MDA-MB-231 cells [32]. In this study, all the apoptosis 
and cell cycle related genes were found deregulated at 
a lower degree by curcumin compared to DK1, which 
might directly contributed to the better sensitivity of 
DK1 on MCF-7. A greater effect of DK1 in activating 
those genes may be directly contributed by the significant 
upregulation of p53, which was found absent in the cur-
cumin treated MCF-7.
Conclusions
In this study, DK1 was found to be more selective than 
curcumin in targeting MCF-7 cell by induction of apop-
tosis and G2/M cell cycle arrest, which might be con-
tributed by the effective overexpression of p53 tumor 
suppressor protein. However, further study to evaluate 
the detail mechanisms and reproducibility of this effect 
in in vivo study is needed to establish a potential for clini-
cal development.
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